Ben Chang - Rich Pharmaceuticals Chairman
Chairman
Mr. Ben Chang was appointed as Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary of Rich Pharmaceuticals, Inc. Mr. Chang served as the Chief Financial Officer and subsequently President and Chief Operating Officer of Biosuccess Biotech Co. LTD., a biopharmaceutical company based in Los Angeles, California. During his tenure at Biosuccess, his responsibilities included arranging and leading all corporate and financial operations in North America. Mr. Chang started his lifescience career as cofounder of SunRich Chemicals, a product development and distribution organization for nutraceuticals. Mr. Chang has over 25 years of pharmaceutical and executive level experience. Mr. Chang also has experience in international banking, VC acquisition, finance, and organizational design and operations since 2013.
| Age | 51 |
| Tenure | 11 years |
| Phone | 323 603 7656 |
| Web | http://www.richpharmaceuticals.com |
Similar Executives
| Found 14 records | CHAIRMAN Age | ||
| John Eaves | Albertsons Companies | 57 | |
| Kevin McNamara | Tyson Foods | 64 | |
| Wesley Edens | Fortress Transp Infra | 53 | |
| Christopher Lynch | Federal Home Loan | 59 | |
| Philip Heasley | Albertsons Companies | 65 | |
| Alan Murray | SunOpta | 54 | |
| Jenne Britell | United Rentals | 74 | |
| Elkin Pianim | Albertsons Companies | N/A | |
| Joseph Adams | Fortress Transp Infra | 66 | |
| Leonard Laufer | Albertsons Companies | 53 | |
| Ronald Nelson | Avis Budget Group | 64 | |
| Jeremy Kendall | SunOpta | 74 | |
| Wesley Taylor | Albertsons Companies | 72 | |
| James Chapman | Albertsons Companies | 53 | |
Management Performance
| Return On Equity | -589.8 |
Rich Pharmaceuticals Leadership Team
Elected by the shareholders, the Rich Pharmaceuticals' board of directors comprises two types of representatives: Rich Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rich. The board's role is to monitor Rich Pharmaceuticals' management team and ensure that shareholders' interests are well served. Rich Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rich Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marcus Laun, CEO, Director | ||
| Ben Chang, Chairman, CEO and President CFO, Treasurer and Secretary | ||
| Richard Salvador, Chief Clinical Officer and Director | ||
| Carol Salvadore, Director |
Rich Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rich Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -589.8 | |||
| Current Valuation | 3.24 M | |||
| Shares Outstanding | 1.88 B | |||
| Shares Owned By Insiders | 0.33 % | |||
| Price To Earning | (0.02) X | |||
| Price To Sales | 8.19 X | |||
| Revenue | 115 K | |||
| Gross Profit | 115 K | |||
| EBITDA | (1.28 M) | |||
| Net Income | (1.69 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Rich Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Rich Pharmaceuticals' short interest history, or implied volatility extrapolated from Rich Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Rich Pharmaceuticals information on this page should be used as a complementary analysis to other Rich Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Rich Stock
If you are still planning to invest in Rich Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rich Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Stocks Directory Find actively traded stocks across global markets |